Triciribine

Drug Profile

Triciribine

Alternative Names: API-2; NSC 154020; NSC 280594; PTX-200 - Prescient Therapeutics; TCN; TCN-P; Tricirbine phosphate monohydrate; VQD-002; VQD-002-ORAL

Latest Information Update: 17 Oct 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of South Florida
  • Developer Albert Einstein College of Medicine; Cahaba Pharmaceuticals; H. Lee Moffitt Cancer Center and Research Institute; Prescient Therapeutics; VioQuest Pharmaceuticals
  • Class Ribonucleosides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; Protein kinase inhibitors; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Breast cancer; Ovarian cancer
  • No development reported Haematological malignancies; Pancreatic cancer; Solid tumours
  • Discontinued Cancer; HIV infections

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Sep 2016 Phase-I/II clinical trials in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT02930109)
  • 04 Feb 2016 Phase-I clinical trials in Acute myeloid leukaemia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top